Silo Pharma, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $1.11 million, or $0.12 per share, compared to a net loss of $928,814, or $0.22 per share, in the same period last year. For the nine months ended September 30, 2025, the company recorded a net loss of $3.35 million, up from $2.66 million in the prior year. Revenue remained stable at $18,025 for both the third quarter of 2025 and 2024, with total revenue for the nine-month period also unchanged at $54,076. The company attributed the increase in net loss primarily to rising operating expenses, which totaled $1.15 million for the quarter, compared to $1.03 million in the previous year.
The company's operating expenses increased significantly, driven by higher compensation costs, professional fees, and research and development expenditures. Compensation expenses rose to $227,132 in Q3 2025 from $169,736 in Q3 2024, reflecting a 33.8% increase. Research and development costs also saw a notable increase, amounting to $543,615 for the quarter, up from $517,548 in the prior year. The total operating expenses for the nine months ended September 30, 2025, reached $3.52 million, compared to $2.94 million in the same period of 2024.
In terms of strategic developments, Silo Pharma has been actively pursuing its product pipeline, which includes therapies targeting PTSD, fibromyalgia, Alzheimer’s disease, and multiple sclerosis. The company has entered into various agreements, including a significant exclusive license agreement with Columbia University for the development of its lead product candidate, SPC-15, an intranasal treatment for PTSD and anxiety disorders. Additionally, Silo Pharma has expanded its focus to include a cryptocurrency treasury strategy, which aims to enhance its financial position through investments in digital assets.
As of September 30, 2025, Silo Pharma reported total assets of $6.38 million, a decrease from $7.41 million at the end of 2024. The company had cash and cash equivalents of $3.92 million and short-term investments of $1.95 million. Notably, current liabilities decreased significantly to $708,339 from $1.66 million, contributing to a working capital of $5.46 million. The company believes it has sufficient liquidity to meet its obligations for at least the next twelve months.
Looking ahead, Silo Pharma plans to continue its focus on developing its therapeutic candidates while also expanding its cryptocurrency strategy. The company has indicated that it expects to increase its research and development activities as it progresses with its existing product candidates and potentially acquires new ones. The management remains optimistic about the future, citing the potential for significant market opportunities in the biopharmaceutical and cryptocurrency sectors.
About Silo Pharma, Inc.
Silo Pharma, Inc. is a biopharmaceutical company developing therapies for underserved neurological and psychiatric conditions, including PTSD, anxiety, fibromyalgia, and Alzheimer's disease. Its focus includes traditional drugs and psychedelic formulations like psilocybin and ketamine. The company collaborates with academic institutions, licenses proprietary technologies, and advances drug candidates through preclinical and clinical stages, aiming to address unmet medical needs with innovative delivery methods and targeted treatments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.